Literature DB >> 23681843

Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Stephanie A C Halvorson1, Erin Gilbert, R Samuel Hopkins, Helen Liu, Charles Lopez, Michael Chu, Marie Martin, Brett Sheppard.   

Abstract

Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the "glucagonoma syndrome." A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe a patient with NME and other features of the glucagonoma syndrome. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Surgical and medical treatment options are reviewed. When detected early, a glucagonoma is surgically curable. It is therefore imperative that clinicians recognize the glucagonoma syndrome in order to make an accurate diagnosis and refer for treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23681843      PMCID: PMC3797362          DOI: 10.1007/s11606-013-2490-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  29 in total

Review 1.  Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema.

Authors:  E A Mullans; P R Cohen
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

2.  Glucagonoma syndrome and necrolytic migratory erythema.

Authors:  Inês Lobo; André Carvalho; Cláudia Amaral; Susana Machado; Rui Carvalho
Journal:  Int J Dermatol       Date:  2010-01       Impact factor: 2.736

Review 3.  Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.

Authors:  Emily P Tierney; Joanna Badger
Journal:  MedGenMed       Date:  2004-09-10

4.  Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin.

Authors:  J D Khandekar; D Oyer; H J Miller; N A Vick
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.

Authors:  E Seregni; L Ferrari; E Bajetta; A Martinetti; E Bombardieri
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

7.  Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.

Authors:  Henrik Kindmark; Anders Sundin; Dan Granberg; Kristina Dunder; Britt Skogseid; Eva Tiensuu Janson; Staffan Welin; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

Review 9.  Clinical review 72: diagnosis and management of functioning islet cell tumors.

Authors:  R R Perry; A I Vinik
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

10.  Population-based study of islet cell carcinoma.

Authors:  James C Yao; Milton P Eisner; Colleen Leary; Cecile Dagohoy; Alexandria Phan; Asif Rashid; Manal Hassan; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

View more
  5 in total

1.  Glucagonoma and the glucagonoma syndrome.

Authors:  Xujun Song; Suli Zheng; Gang Yang; Guangbing Xiong; Zhe Cao; Mengyu Feng; Taiping Zhang; Yupei Zhao
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

2.  Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor.

Authors:  Sheng-li Wu; Ji-gang Bai; Jun Xu; Qing-yong Ma; Zheng Wu
Journal:  World J Surg Oncol       Date:  2014-07-17       Impact factor: 2.754

3.  Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.

Authors:  Hameem I Kawsar; Alma Habib; Azhar Saeed; Anwaar Saeed
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-11-01

4.  Case of delayed diagnosis of necrolytic migratory erythema.

Authors:  Wissal Abdelli; Fatima Alaoui; Asmahen Souissi; Wiem Sassi; Ines Chelly; Slim Haouet; Mourad Mokni
Journal:  Clin Case Rep       Date:  2021-12-11

5.  How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

Authors:  Carmen Sorina Martin; Ovidiu Dumitru Parfeni; Liliana Gabriela Popa; Mara Madalina Mihai; Dana Terzea; Vlad Herlea; Mirela Gherghe; Razvan Adam; Osama Alnuaimi; Valentin Calu; Adrian Miron; Silvius Negoita; Cornelia Nitipir; Simona Fica
Journal:  Diagnostics (Basel)       Date:  2022-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.